A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies
Public ClinicalTrials.gov record NCT00730639. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-Label, Multicenter, Multidose, Dose Escalation Study of BMS-936558 (Nivolumab) in Subjects With Selected Advanced or Recurrent Malignancies
Study identification
- NCT ID
- NCT00730639
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 395 participants
Conditions and interventions
Conditions
Interventions
- BMS-936558 (MDX-1106) Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 29, 2008
- Primary completion
- Feb 3, 2013
- Completion
- Dec 21, 2020
- Last update posted
- Dec 2, 2021
2008 – 2020
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pinnacle Oncology Hematology | Scottsdale | Arizona | 85258 | — |
| Yale University School Of Medicine | New Haven | Connecticut | 06520 | — |
| H. Lee Moffitt Cancer Center & Research Institute | Tampa | Florida | 33612-9497 | — |
| Johns Hopkins University | Baltimore | Maryland | 21231 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02215 | — |
| University Of Michigan Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Memorial Sloan Kettering Nassau | New York | New York | 10065 | — |
| Carolina Biooncology Institute | Huntersville | North Carolina | 28078 | — |
| Christ Hospital | Cincinnati | Ohio | 45219 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Vanderbilt-Ingram Cancer Ctr | Nashville | Tennessee | 37232 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00730639, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 2, 2021 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00730639 live on ClinicalTrials.gov.